The pharmaceutical sponsor of Gilenya (fingolimod), Novartis, has this week reported one case of Progressive Multifocal Leukoencephalopathy (PML) in an individual currently being treated with Gilenya in Europe. To read more click on the following link
Article courtesy of MS Research Australia www.msra.org.au